Sepsis and sepsis-associated acute kidney injury (SA-AKI) are critical public health challenges, marked by high incidence rates, high mortality and long term damaging effects to multiple organ systems. Despite ongoing efforts, current therapeutic options remain limited in their effectiveness and scope.
At Eliaz Therapeutics, we have developed a patented and innovative medical device specifically designed to remove Galectin-3 (Gal-3) from human blood.
This device, effectively eliminates Gal-3 from the circulation, offering offering a much needed solution where there is none.
Our device represents a breakthrough in addressing the significant unmet need for effective interventions in the treatment of sepsis and SA-AKI.
Our groundbreaking Proof of Concept began with a large animal study, where our device demonstrated a remarkable ability to reduce inflammation and fibrosis. The visual evidence below highlights the difference between control and experimental groups. These compelling results were published in a peer-reviewed journal by MGH Harvard. Building on this success, further studies in both small and large animal models of sepsis have shown encouraging results, reinforcing the potential of our device in combating sepsis and its complications.
